The Short-Term Cost-Effectiveness of Once-Daily Liraglutide Versus Once-Weekly Exenatide for the Treatment of Type 2 Diabetes Mellitus in the United States

BACKGROUND: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease with substantial morbidity, mortality, and economic impacts. Glucagon-like peptide-1 (GLP-1) receptor agonists, such as once-daily (QD) liraglutide and once-weekly (QW) exenatide, are FDA-approved treatment for T2DM. Head-to-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bruce, Roth, Joshua A., Nguyen, Hiep, Felber, Eugene, Furnback, Wes, Garrison, Louis P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388383/
https://www.ncbi.nlm.nih.gov/pubmed/25849542
http://dx.doi.org/10.1371/journal.pone.0121915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388383/
https://www.ncbi.nlm.nih.gov/pubmed/25849542
http://dx.doi.org/10.1371/journal.pone.0121915

Ejemplares similares